About us Leadership History News Clinical Trials Publications Contact us Leadership Building on our team’s broad global experiences and capabilities to develop and commercialize therapies, Immunicom is accelerating the path to make immunotherapies accessible to broad-based patient populations via partnerships with leading hospitals around the world. Leveraging a proprietary technology platform, we are on a mission to dramatically shorten the time to develop important immunotherapies, sometimes by as much as two-thirds, significantly reducing the time required to bring safe and effective immunotherapies to market. Collectively, our leadership team and its board members have commercialized more than 50 pharmaceuticals and therapeutic devices, generating billions of dollars in value and bringing meaningful therapies to innumerable patients who need them. Whether it is securing funding or regulatory approval or overseeing clinical trials and device development, our accomplished team produces results. Immunicom is developing a revolutionary new treatment that addresses issues still plaguing the healthcare industry: side effects, quality of life, and cost. Amir Jafri, CEO & Founder Our team Amir Jafri CEO, Founder Read bio Linkedin Raju Chauhan Chief Operating Officer Read bio Linkedin Steve Prince Chief Commercial Officer Read bio Linkedin Dave L. Lopez, Esq., CPA CFO, General Counsel Read bio Linkedin Victoria Manax, M.D. Chief Clinical Officer Read bio Linkedin Robert Segal, M.D., F.A.C.P. Chief Medical Officer Read bio Lawrence Florin Executive Vice President of Clinical Operations Read bio Linkedin Annette Marleau, Ph.D. Vice President of Research and Development Read bio Christian Shenouda, M.D. Vice President of Regulatory Affairs Read bio Steven Josephs, Ph.D. Chief Scientist Read bio Linkedin Farah Awan Vice President of Business Operations Read bio Johan Louw Vice President of Strategic Programs Read bio Linkedin Marilyn Panahi Director of Quality Assurance Read bio Linkedin Adam Ostrowski, M.D. Medical Director, International Read bio Linkedin Regina Deck, RN, MSN, OCN, CCRP Executive Director of Clinical Affairs Read bio Linkedin Board of directors Amir Jafri Read bio David Schlotterbeck Read bio Gary Pace, Ph.D. Read bio D. John Miller Read bio Michael Perry Read bio Michael Barrett Read bio Cooper H. Miller Read bio John Rompon Read bio Wayne Jonas, M.D. – Board Observer Read bio Get in touch today Let’s talk about what we can achieve together Contact us Learn more about our team Who are we Immunicom Inc. HEADQUARTERS San Diego, CA RESOURCES Terms of Use Privacy policy GET IN TOUCH Contact us Newsletter Subscription Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe. © 2021 — Immunicom, Inc. All Rights Reserved. We use cookies and similar technologies to enable services and functionality on our site and to understand your interaction with our service. By clicking on accept, you agree to our use of such technologies for marketing and analytics. Cookie settings Accept all